Efficacy of Kan Jang^® in Patients with Mild COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial.

ABSTRACT: Background and aim. This study aimed to assess the efficacy of the treatment of Kan Jang^®, a fixed combination of Andrographis paniculata (Burm. F.) Wall. ex. Nees and Eleutherococcus senticosus (Rupr. & Maxim.) Maxim extracts in patients with mild symptoms of COVID-19. Methods. One hundred and forty patients received six capsules of Kan Jang^® (n = 68, daily dose of andrographolides-90 mg) or placebo (n = 72) and supportive treatment (paracetamol) for 14 consecutive days in a randomized, quadruple-blinded, placebo-controlled, two-parallel-group design. The efficacy outcomes were the rate of cases turning to severe, the detection rate of coronavirus SARS-CoV-2 over the time of treatment, the duration, and the seve

SUBMITTER: Ratiani L 

PROVIDER: S-EPMC10535596 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature